|
Jul 1
|
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
|
|
Jan 17
|
Avacta Therapeutics reports data from trial of AVA6000 for salivary gland cancer
|
|
Dec 30
|
While institutions own 41% of Avacta Group Plc (LON:AVCT), individual investors are its largest shareholders with 57% ownership
|
|
Oct 3
|
Avacta Group First Half 2024 Earnings: UK£0.038 loss per share (vs UK£0.043 loss in 1H 2023)
|
|
Jul 23
|
Avacta Group Plc's (LON:AVCT) largest shareholders are retail investors with 58% ownership, institutions own 41%
|
|
Dec 19
|
Appointment of Chief Business Officer
|
|
Nov 30
|
Levicept Appoints Eliot Forster as CEO
|
|
Sep 7
|
Avacta Group Plc (LON:AVCT) is largely controlled by institutional shareholders who own 53% of the company
|
|
Apr 27
|
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
|